HCPCS Code J2469: palonosetron billing guide (2026)

Key Takeaways

HCPCS code J2469 describes the injection of palonosetron HCl, 25 mcg, billed primarily for chemotherapy-induced nausea and vomiting (CINV) prevention.

One unit of J2469 equals 25 mcg of palonosetron HCl. Billing the wrong unit size is the most common J2469 claim error.

Medicare Part B reimburses J2469 at ASP+6%, with rates updated quarterly. Always verify current rates against the CMS ASP drug pricing file before submitting claims.

Practice management software like Pabau helps capture accurate dose, NDC, and diagnosis data at the point of care, so J2469 claims start from clean documentation.

HCPCS code J2469 is the Medicare Part B billing code for an injection of palonosetron HCl, 25 mcg, used mainly to prevent chemotherapy-induced nausea and vomiting (CINV).

One unit equals 25 mcg of palonosetron HCl, so a standard 0.25 mg (250 mcg) dose bills as 10 units. Notably, billing it as a single unit, a 10x underbilling error, is the mistake that shows up most often on J2469 claims, alongside a missing National Drug Code (NDC).

This reference covers the official descriptor, active code status for 2025 and 2026, Medicare reimbursement methodology, ICD-10 diagnosis pairings, NDC crosswalk, prior authorization, and the billing errors most likely to trigger a denial.

HCPCS code J2469: description, status, and code details

J2469 is a Level II HCPCS code maintained by the Centers for Medicare and Medicaid Services (CMS). Specifically, it belongs to the Drugs Administered Other Than Oral Method category, covering physician-administered injectable medications billed under Medicare Part B.

First, coders should verify active status annually. CMS may revise, delete, or update HCPCS descriptors each January 1, as it did for P9043, another Part B drug code with its own unit-of-service basis. The AAPC HCPCS code database and the CMS annual HCPCS update files are the most reliable sources for confirming current status.

Palonosetron (Aloxi / Posfrea): drug overview for billing staff

Palonosetron hydrochloride is a second-generation 5-HT3 receptor antagonist antiemetic. Unlike first-generation 5-HT3 antagonists such as ondansetron, palonosetron has a higher binding affinity and a significantly longer plasma half-life (roughly 40 hours), which supports its use as a single pre-chemotherapy dose.

Two brand names map to J2469. Aloxi (manufactured by Eisai) is the original branded formulation, available as a 0.25 mg/5 mL single-dose vial. Meanwhile, Posfrea (Avyxa Pharma) is a newer branded version. Generic palonosetron formulations are also available and bill under the same J2469 code when the NDC is reported correctly on the claim.

• FDA-approved indications for palonosetron:
• Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
• Prevention of postoperative nausea and vomiting (PONV) in adults
• Route of administration: Intravenous injection only
• Standard adult dose for CINV: 0.25 mg (250 mcg) administered as a single IV bolus approximately 30 minutes before chemotherapy

For billing purposes: a 0.25 mg (250 mcg) dose administered to a single patient equals 10 units of J2469, because one unit equals 25 mcg. Consequently, this unit calculation is where most billing errors originate.

Clinical indications and CINV prevention billing context

J2469 is most commonly billed in outpatient infusion centers, hospital outpatient departments, and oncology physician offices. Understanding infusion clinic best practices matters here: the clinical setting determines the place of service (POS) code on the claim, which affects reimbursement rates.

Medicare Part B covers J2469 when it is physician-administered in an eligible setting. In addition, the drug must be reasonable and necessary for the patient’s condition under Medicare’s coverage framework. However, palonosetron administered in a hospital inpatient setting is typically bundled into the DRG payment and is not separately billed under J2469.

Similarly, ambulatory surgical settings, including plastic surgery practices, commonly administer palonosetron for PONV prevention before same-day discharge.

J2469 Medicare fee schedule and reimbursement rates

Medicare Part B reimburses physician-administered drugs under J2469 using the Average Sales Price (ASP) methodology. The standard reimbursement rate is ASP+6% for non-facility settings. By contrast, facility settings (such as hospital outpatient departments) typically receive a rate based on the hospital outpatient prospective payment system (HOPPS) rather than the ASP+6% formula.

ASP-based rates update every calendar quarter. Therefore, billing staff should verify current rates directly from the quarterly ASP Drug Pricing File, or the OPPS Addendum B/APC file for facility rates, before submitting claims. Rates listed in third-party databases may lag by one or more quarters.

340B-acquired palonosetron reimburses at ASP+6%, the same rate as non-340B claims. CMS restored this rate in September 2022, after American Hospital Association v. Becerra struck down the earlier 340B-specific cut.

Covered entities now report modifier TB on 340B-acquired drug lines. TB is informational only, tied to the Part B inflation-rebate program, and doesn’t change the payment amount. CMS discontinued modifier JG for 340B reporting effective January 1, 2025, so it should no longer appear on these claims.

Billing guidelines and units of service for J2469

Getting units right is the single most important billing discipline for J2469. One unit equals 25 mcg. For example, a standard adult CINV prevention dose is 0.25 mg (250 mcg), which equals 10 units on the claim. Good medical documentation workflows that capture the administered dose at the point of care reduce transcription errors before the claim is built.

• Unit calculation: Divide the administered dose in mcg by 25. Example: 250 mcg administered = 10 units billed.
• Administration code pairing: Bill J2469 alongside the appropriate infusion/injection administration code. IV push: CPT 96374. Initial infusion (rare for palonosetron): CPT 96365.
• NDC reporting: Required on all Medicare Part B claims for J2469. Report the 11-digit NDC, the unit qualifier (UN for units), and the quantity dispensed using the CMS-mandated format on the claim.
• Modifier usage: Append TB for 340B-acquired drugs (informational, not a payment adjuster), GY (item or service not covered), or KX (requirements met) where applicable per payer-specific instructions. JG was discontinued for 340B reporting effective January 1, 2025.
• Place of service: Must match the actual setting where the drug was administered. POS mismatches are a common audit trigger.

Pabau’s practice management platform helps capture accurate dose, NDC, and place-of-service data at the point of care, so that information is already correct by the time a claim is built, reducing the errors that lead to denials or post-payment audits.

NDC to HCPCS crosswalk for J2469

Medicare requires that a National Drug Code (NDC) be reported on all Part B drug claims, including J2469. In other words, the NDC identifies the exact manufacturer and formulation dispensed. Practices managing injectable drug inventories benefit from IV therapy EMR software that stores NDC data at the product level and pre-populates it on claims.

NDC numbers change when drug lots or manufacturer packaging changes. Accordingly, always verify the NDC for the specific vial dispensed using the FDA NDC directory or the manufacturer’s current prescribing information. Reporting an outdated or incorrect NDC on a claim is a compliance risk that can trigger a refund request after post-payment audit.

J2469 ICD-10 diagnosis codes: supported pairings

Every J2469 claim requires a supporting ICD-10-CM diagnosis code that establishes medical necessity. In particular, the pairing must reflect the patient’s documented clinical condition, most often nausea and vomiting under a code such as R11.2, or an encounter code for chemotherapy.

When palonosetron is given as CINV prophylaxis during a chemotherapy encounter, Z51.11 is typically the appropriate primary diagnosis code. The patient’s active malignancy diagnosis should also appear on the claim as a secondary diagnosis to fully support medical necessity. Additionally, the chemotherapy itself is billed separately, typically under an administration code such as 96413.

Prior authorization requirements for J2469

Medicare Part B does not generally require prior authorization for J2469. The drug is covered as a medically necessary physician-administered antiemetic under the Part B drug benefit, and CMS has not identified it as a code requiring prior auth under current Medicare programs.

Commercial and managed care payers are a different matter. Understanding medical spa compliance workflows that track prior auth requirements by payer is relevant for any injectable drug code. Moreover, many commercial insurers and Medicare Advantage plans require prior authorization for antiemetics, particularly when used outside their preferred formulary or before a certain number of prior antiemetic trials are documented.

• Medicare Part B (traditional): No prior authorization required for J2469 in most jurisdictions.
• Medicare Advantage plans: PA requirements vary by plan. Check each patient’s plan documents before administering palonosetron.
• Commercial insurers: Many require documentation of prior antiemetic therapy failure or a step-therapy protocol before approving palonosetron. Check payer-specific prior auth lists.
• MAC/LCD-specific coverage: No single national policy article governs injectable antiemetic coverage. Coverage rules for J2469 are set locally by each Medicare Administrative Contractor; check the applicable LCD for antiemetics in your jurisdiction.

Manage injectable drug billing in one workflow

Pabau's practice management platform helps oncology and infusion practices capture accurate units, NDC data, and diagnosis codes at the point of care for J-code billing like J2469, so claims start from clean documentation.

Book a demo

CMS coverage policy for J2469

No single national policy article governs injectable palonosetron. CMS policy article A52480 (Oral Antiemetic Drugs, Replacement for Intravenous Antiemetics) covers oral alternatives dispensed by DME suppliers, such as aprepitant, rolapitant, and netupitant/palonosetron capsules, not the injectable form billed under J2469.

Coverage for injectable antiemetics instead follows Local Coverage Determinations (LCDs) issued by each Medicare Administrative Contractor (MAC). Practices billing J2469 at scale, particularly infusion centers managing IV therapy software, should confirm the applicable MAC’s LCD as part of their billing compliance protocols.

• Covered: CINV prevention in patients receiving moderately or highly emetogenic chemotherapy regimens; PONV prevention in adults undergoing surgery.
• Non-covered: Palonosetron is not separately billable when administered in a hospital inpatient setting (bundled into the DRG). It is also not covered when administered for non-FDA-approved indications without supporting LCD coverage.
• LCD/NCD applicability: No specific national coverage determination (NCD) applies to palonosetron. Local coverage determinations (LCDs) issued by Medicare Administrative Contractors (MACs) may apply by jurisdiction. Billing staff should verify the applicable MAC’s LCD for antiemetics.

Documentation requirements for J2469

A defensible J2469 claim rests on documentation that all points to the same dose, drug, and diagnosis. In short, missing or mismatched records are what turn an otherwise clean claim into an audit finding.

• Physician order: the ordered dose and route, signed before the drug is administered.
• Drug administration record: the actual dose given, confirming the units billed match what was administered.
• NDC per dispensed vial: the National Drug Code for the specific vial used, tied to the unit count on the claim.
• Place-of-service documentation: the chart confirms where the drug was given, matching the POS code on the claim.
• Medical necessity and ICD-10 support: the diagnosis code reflects the documented clinical indication, meeting the applicable MAC’s LCD criteria where one exists.

Where nausea and vomiting are the primary symptom driving treatment, the chart should reflect a structured symptom review rather than a vague note, similar to the approach in a gastrointestinal assessment guide. Ultimately, keeping the order, the administration record, the NDC, and the diagnosis aligned before the claim is built prevents most J2469 denials before they happen.

Common billing errors to avoid with HCPCS code J2469

No competitor reference page dedicates a section to J2469-specific billing errors. Indeed, this is where most denials originate, and the patterns are consistent enough to systematize. Practices using digital intake forms that capture dose, NDC, and setting at the point of care catch most of these errors before the claim is built.

For broader HIPAA compliance context that governs how patient data and billing records are handled, HIPAA compliance guidance provides the documentation and records retention framework that applies to injectable drug billing workflows.

Related HCPCS codes and antiemetic alternatives

When palonosetron is contraindicated or unavailable, billing staff may need to code for alternative antiemetics, or for other supportive-care drugs used during the same chemotherapy visit, such as filgrastim (J1442) for neutropenia prevention. The table below lists the most common antiemetic J-codes for cross-reference.

For a comprehensive lookup of HCPCS Level II codes including antiemetic J-codes, the PGM Billing lookup tool provides free search using CMS source data.

Conclusion

Unit-of-service errors and missing NDCs account for the majority of J2469 denials. One unit equals 25 mcg: every claim starts there. From that foundation, correct place of service, appropriate ICD-10 pairing (Z51.11 for chemotherapy encounters), and modifier accuracy for 340B settings determine whether the claim pays cleanly or triggers a rework cycle.

Pabau’s practice management platform helps infusion and oncology-adjacent clinics embed these billing rules at the point of care, so unit counts, NDC data, and POS codes are captured correctly before the claim is submitted. To see how Pabau handles injectable drug billing workflows for your practice, book a demo with the team.

Continue your research

Need accurate dose and NDC data before a claim is built? Pabau’s digital intake forms capture unit, NDC, and diagnosis details at the point of care for injectable drug codes like J2469.

Running an infusion or IV therapy clinic? Pabau’s IV therapy software supports the clinical and billing workflows specific to infusion-based practices.

Looking for guidance on digital forms and documentation workflows? Pabau digital forms capture the clinical data billing teams need at the point of care, reducing transcription errors downstream.

Frequently asked questions